Compare Repligen Corporation Common Stock (RGEN) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Direxion Daily FTSE China Bull 3x Shares trades at $24.12 (market cap $600.54M). The key difference: Repligen Corporation Common Stock is far larger — about 18.5× Direxion Daily FTSE China Bull 3x Shares's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Direxion Daily FTSE China Bull 3x Shares for 26 Days on average.
| RGEN | YINN | |
|---|---|---|
Market Cap | $11.14B | $600.54M |
Volume | 1,259,263 | 729,546 |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.57 | $52.69 |
52-Week Low | $102.87 | $21.45 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
YINN trades at $25.06, up 0.36% with bearish technical signals from moving averages. The stock shows neutral momentum oscillators with RSI at 44.85. Recent news highlights China's economic policies affecting Asian markets, though YINN's specific financial metrics remain undisclosed in current data. The stock faces concentrated support/resistance around $25.
Outlook remains cautious with technical indicators suggesting bearish pressure. Investment opportunity depends on China's economic recovery and policy developments. Key risks include regulatory changes and market volatility. Analyst consensus and institutional positioning data are currently unavailable for assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
